JP5688031B2 - ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療 - Google Patents

ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療 Download PDF

Info

Publication number
JP5688031B2
JP5688031B2 JP2011543955A JP2011543955A JP5688031B2 JP 5688031 B2 JP5688031 B2 JP 5688031B2 JP 2011543955 A JP2011543955 A JP 2011543955A JP 2011543955 A JP2011543955 A JP 2011543955A JP 5688031 B2 JP5688031 B2 JP 5688031B2
Authority
JP
Japan
Prior art keywords
botulinum toxin
soft tissue
treatment
administration
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011543955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514579A (ja
JP2012514579A5 (enExample
Inventor
ロバート ジョン ペトレラ，
ロバート ジョン ペトレラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42311846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5688031(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2012514579A publication Critical patent/JP2012514579A/ja
Publication of JP2012514579A5 publication Critical patent/JP2012514579A5/ja
Application granted granted Critical
Publication of JP5688031B2 publication Critical patent/JP5688031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011543955A 2009-01-07 2010-01-06 ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療 Active JP5688031B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14294109P 2009-01-07 2009-01-07
US61/142,941 2009-01-07
PCT/CA2010/000008 WO2010078648A1 (en) 2009-01-07 2010-01-06 Treatment of soft tissue injury using hyaluronic acid and botulinum toxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014161022A Division JP2014208705A (ja) 2009-01-07 2014-08-07 ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療

Publications (3)

Publication Number Publication Date
JP2012514579A JP2012514579A (ja) 2012-06-28
JP2012514579A5 JP2012514579A5 (enExample) 2013-02-21
JP5688031B2 true JP5688031B2 (ja) 2015-03-25

Family

ID=42311846

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011543955A Active JP5688031B2 (ja) 2009-01-07 2010-01-06 ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療
JP2014161022A Withdrawn JP2014208705A (ja) 2009-01-07 2014-08-07 ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014161022A Withdrawn JP2014208705A (ja) 2009-01-07 2014-08-07 ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療

Country Status (7)

Country Link
US (1) US9072779B2 (enExample)
EP (1) EP2381956B9 (enExample)
JP (2) JP5688031B2 (enExample)
AU (1) AU2010204445B2 (enExample)
CA (1) CA2749034C (enExample)
ES (1) ES2538835T3 (enExample)
WO (1) WO2010078648A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
JP6357228B2 (ja) * 2013-07-10 2018-07-11 マトリックス バイオロジー インスティテュート 高い弾性を有するヒアルロナンの組成物およびその使用
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2015115113A1 (ja) * 2014-01-31 2015-08-06 テルモ株式会社 穿刺補助器具および穿刺器具セット
HUE054874T2 (hu) 2015-09-24 2021-10-28 Matrix Biology Inst Magas elaszticitású hialuronán készítmények és alkalmazási eljárások
KR20180114891A (ko) * 2016-03-02 2018-10-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소를 포함하는 조성물
WO2018216974A2 (ko) * 2017-05-24 2018-11-29 주식회사 에이티지씨 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
NZ540425A (en) * 2002-12-20 2009-03-31 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
SI1677806T1 (sl) 2003-10-09 2009-06-30 Robert John Petrella Postopki za zdravljenje akutnega in s preobremenitvijo povzročenega zvina in natega z uporabo hialuronske kisline
KR20070034128A (ko) * 2004-07-22 2007-03-27 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 통신 시스템 및 방법과, 이들의 사용 및 이동 노드
WO2006020208A2 (en) 2004-07-26 2006-02-23 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition whit a botulinum neurotoxin
PL1853303T3 (pl) * 2005-02-14 2016-05-31 Dpm Therapeutics Corp Stabilizowane kompozycje do podawania miejscowego i sposoby ich otrzymywania
FR2896693B1 (fr) 2006-01-27 2008-03-14 Sod Conseils Rech Applic Composition comprenant plusieurs toxines botuliques

Also Published As

Publication number Publication date
AU2010204445B2 (en) 2015-09-03
CA2749034C (en) 2019-01-15
AU2010204445A1 (en) 2011-07-28
EP2381956B9 (en) 2016-11-23
CA2749034A1 (en) 2010-07-15
WO2010078648A1 (en) 2010-07-15
JP2012514579A (ja) 2012-06-28
EP2381956B1 (en) 2015-04-22
EP2381956A4 (en) 2013-01-02
ES2538835T3 (es) 2015-06-24
EP2381956A1 (en) 2011-11-02
US20100172940A1 (en) 2010-07-08
JP2014208705A (ja) 2014-11-06
US9072779B2 (en) 2015-07-07

Similar Documents

Publication Publication Date Title
JP5688031B2 (ja) ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療
Tascioglu et al. Short-term effectiveness of ultrasound therapy in knee osteoarthritis
JP2016185989A (ja) ヒアルロン酸を使用する急性及び過用性の捻挫及び筋違いの治療方法
Pavelka et al. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®) vs hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study
Park et al. Treatment effects of ultrasound-guided capsular distension with hyaluronic acid in adhesive capsulitis of the shoulder
Mun et al. Clinical efficacy of hydrodistention with joint manipulation under interscalene block compared with intra-articular corticosteroid injection for frozen shoulder: a prospective randomized controlled study
Witteveen et al. A prospective multi-centre, open study of the safety and efficacy of hylan GF 20 (Synvisc®) in patients with symptomatic ankle (talo-crural) osteoarthritis
Carulli et al. Intra-articular injections of hyaluronic acid induce positive clinical effects in knees of patients affected by haemophilic arthropathy
Lee et al. Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: open-label, randomized, multicentre clinical trial
Kim et al. Does hyaluronate injection work in shoulder disease in early stage? A multicenter, randomized, single blind and open comparative clinical study
Yilmaz The evaluation of the effectiveness of intra-articular steroid, tenoxicam, and combined steroid–tenoxicam injections in the treatment of patients with knee osteoarthritis
Lee et al. Effect of hypertonic saline in intra-articular hydraulic distension for adhesive capsulitis
Zorzi et al. A new hydrogel for the conservative treatment of meniscal lesions: a randomized controlled study
Witteveen et al. The optimal injection technique for the osteoarthritic ankle: a randomized, cross-over trial
Lynen Treatment of chronic tendinopathies with peritendinous hyaluronan injections under sonographic guidance—an interventional, prospective, single-arm, multicenter study, Dtsch
Petrella et al. Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee
ÖRÜCÜ ATAR et al. Ultrasound-Guided Hydrodissection Combined with Peripheral Nerve Block for the Treatment of Post-Traumatic Knee Stiffness.
Irsay et al. Effectiveness of glucosamine and chondroitin sulfate combination in patients with primary osteoarthritis
Horner et al. Evidence-based approach to the nonoperative management of FAI
Gumustas Deniz Gulabi, Mehmet Ali Uysal, Ahmet Akça, Ilker Colak, Gultekin Sıtkı Çeçen
Gosikonda et al. Role of viscosupplementation in the management of primary osteoarthritis knee
Anderson Complex regional pain syndrome/reflex sympathetic dystrophy: difficult to diagnose, difficult to treat
Sun et al. Hyaluronate for the Treatment of Ankle Osteoarthritis
Sun et al. Effects of Intraarticular Botulinum Toxin A in the Treatment of Ankle Osteoarthritis
PIOVaN A new hydrogel for the conservative treatment of meniscal lesions: a randomized controlled study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140605

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150123

R150 Certificate of patent or registration of utility model

Ref document number: 5688031

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250